Macular Pucker

A macular pucker, known medically as epiretinal membrane (ERM), is an abnormal, thin layer of fibrous scar-like tissue that grows on the inner surface of the macula, the central part of the retina responsible for sharp, detailed vision. As this membrane gradually contracts, it wrinkles the retinal surface beneath it—much like a piece of cellophane shrinking over a smooth surface—distorting central vision and reducing visual clarity. The condition belongs to the broader category of vitreoretinal interface disorders: conditions affecting the junction where the vitreous gel (the clear gel filling the interior of the eye) meets the inner surface of the retina. Macular pucker has been described in the medical literature since 1865 and is known by a number of alternate names, including preretinal macular fibrosis, cellophane maculopathy, and surface wrinkling retinopathy—all referring to the same abnormal membrane at the macular surface.

Macular pucker is one of the most common retinal conditions in adults over age 50, and one of the most commonly treated. An estimated 30 million Americans have an epiretinal membrane in at least one eye. A large population study—the Multi-Ethnic Study of Atherosclerosis (MESA), supported by the National Institutes of Health (NIH)—found an overall ERM prevalence of about 29% among adults aged 45 to 84. The majority of these are mild, early forms that cause no symptoms. The more advanced, symptomatic form—macular pucker—affects approximately 3.8% of adults in this age range and becomes more common with each decade of life, rising from under 1% in adults aged 45 to 54 to about 6.5% by ages 65 to 74. Most cases are discovered incidentally during a routine dilated eye exam.

While a macular pucker is not life-threatening, it can meaningfully reduce quality of life through central vision distortion and reduced reading ability. The good news is that it is highly treatable when symptoms become significant—vitreoretinal surgery to remove the membrane leads to visual improvement in approximately 58–70% of patients. The sooner treatment is undertaken before the membrane has caused severe structural damage to the retina, the better the visual outcome.

The formation of a macular pucker begins when cells that normally live elsewhere in the eye migrate onto the inner surface of the macula and form a fibrocellular layer. In idiopathic macular pucker, the trigger is almost always posterior vitreous detachment (PVD)—the normal age-related separation of the vitreous gel from the retinal surface. As the vitreous pulls away, it creates tiny defects in the innermost layer of the retina (the internal limiting membrane, or ILM). Through these microscopic entry points, various cell types—including Müller glial cells, vitreous-resident immune cells called hyalocytes, and cells from the retinal pigment epithelium—migrate onto the retinal surface. Once there, these cells are exposed to a powerful growth factor called transforming growth factor-beta 1 (TGF-beta 1), which drives them to transform into contractile myofibroblast-like cells. These transformed cells deposit collagen and other structural proteins, building the scar-like membrane. As the membrane matures, it contracts—applying centripetal (inward) tractional forces to the macula—which wrinkles the retinal surface and distorts the photoreceptors that produce sharp central vision. TGF)-beta 1 levels in the eye correlate strongly with ERM severity, confirming its central role in the progression of this condition. Other contributing causes include:

• Age-related posterior vitreous detachment: present in 70–95% of idiopathic ERM cases. PVD is the initiating event in the vast majority of cases, making advancing age the primary driver of the condition.
• Postmenopausal estrogen changes: The three-fold excess of macular pucker seen in women in some series may relate to estrogen’s role in supporting retinal glial cell health. After menopause, loss of estrogen may increase vulnerability of the macula to the cellular changes that drive ERM formation.
• Intraocular inflammation or surgery: In secondary ERM, disruption of the blood-retinal barrier from disease or surgical trauma releases inflammatory cells and activates fibroblast-like cells, initiating the same proliferative process at the macular surface.
• Retinal vascular disease: Diabetic retinopathy and retinal vein occlusion disrupt the inner retinal surface and promote ERM through inflammatory and ischemic mechanisms.

The following factors are associated with a higher likelihood of developing a macular pucker, drawn from the Multi-Ethnic Study of Atherosclerosis (MESA)—a large NIH-supported population study of adults aged 45 to 84.

• Older age: the strongest independent predictor. The risk of the symptomatic form (preretinal macular fibrosis) increases 1.8-fold for every 10-year increase in age. Prevalence rises from under 1% in adults aged 45 to 54 to about 6.5% by ages 65 to 74.
• Diabetes mellitus: People with diabetes have approximately three times the risk of developing symptomatic macular pucker compared to those without diabetes, even before any visible diabetic retinopathy is present on examination. This likely reflects subclinical vascular and inflammatory changes at the vitreoretinal interface driven by chronic hyperglycemia.
• Prior cataract surgery: About 50% of eyes that have had cataract surgery develop some degree of ERM on imaging, making this the most strongly associated secondary cause. The surgical manipulation activates retinal pigment epithelium cells and fibroblasts at the macular surface.
• Chinese ethnicity: The highest prevalence of macular pucker of any racial group in the MESA study was found in Chinese American adults, with an odds ratio of 2.58 for the symptomatic form compared to white adults. The mechanism is not yet fully understood.
• Retinal vein occlusion: Approximately 38% of eyes with a history of retinal vein occlusion have ERM on imaging.
• Diabetic retinopathy: Approximately 33% of eyes with documented diabetic retinopathy have ERM.
• Smoking: Cigarette smoking carries approximately 2.5 times the risk of symptomatic macular pucker in some analyses.
• Protective factor: Black race: Black adults in the MESA study had significantly lower rates of the symptomatic form of macular pucker compared to white adults (odds ratio 0.52), making this one of the few conditions in ophthalmology where Black patients demonstrate a protective demographic profile for a specific retinal disease.

There is no population-wide screening program specifically for macular puckers. The condition is most often detected incidentally during a routine dilated eye examination, or when a patient reports symptoms of central visual distortion and is referred for further evaluation. The American Academy of Ophthalmology and the NIH recommend annual dilated eye examinations for all adults beginning at age 50, and more frequently for those with diabetes, cardiovascular risk factors, or a history of prior ocular surgery. Because macular pucker is so common in adults over 60 and because early-stage disease is entirely asymptomatic, many people have the condition without knowing it. Detecting it early—before the membrane has advanced to stage 3 or stage 4 on OCT—means that surgical intervention, if it becomes necessary, can be offered when the retinal architecture is still largely preserved and visual outcomes are best.

Idiopathic macular pucker cannot be prevented. There is no known intervention that prevents the age-related posterior vitreous detachment that initiates the membrane, or that prevents the cellular proliferation that follows. For secondary macular pucker, however, several approaches reduce risk:

• Optimal diabetes management: Maintaining blood sugar levels within a healthy range and having timely treatment for any signs of diabetic retinopathy significantly reduces the risk of secondary ERM in people with diabetes.
• Prompt treatment of retinal tears: Laser or cryotherapy treatment of retinal tears before they progress to detachment prevents the retinal trauma that can trigger secondary ERM formation.
• Management of uveitis: Controlling intraocular inflammation with appropriate anti-inflammatory treatment reduces the likelihood of secondary ERM in patients with chronic eye inflammation.
• Annual dilated eye exams from age 50: Early detection allows referral for surgery at the optimal stage before irreversible photoreceptor damage occurs.

The hallmark symptom of symptomatic macular pucker is metamorphopsia—the perception that straight lines appear wavy, bent, or distorted. This occurs because the contracting membrane physically wrinkles the photoreceptors that normally lie in a precise, flat arrangement at the macula. The distortion is most noticeable when looking at grids of lines, door frames, text on a page, or tiles on a floor. Many patients first notice the symptom when they accidentally cover one eye and see that the world looks distorted or blurred through the affected eye.

It is important to know that many cases of macular pucker—particularly the early, grade 0 form visible only on examination—cause no symptoms at all. The proportion of people with mild ERM who have any measurable vision impairment is similar to the proportion without ERM, reflecting how commonly this condition is present without causing any functional problem. Common signs and symptoms when the membrane is symptomatic include:

• Metamorphopsia (central visual distortion): Straight lines appear wavy or bent when looking with the affected eye. This is the most characteristic symptom and the one that most commonly prompts patients to seek evaluation.
• Reduced central visual acuity: Central vision ranges from mildly blurred to significantly impaired. In moderate-to-advanced disease, acuity typically falls between 20/30 and 20/200 in the affected eye.
• Micropsia: Objects appear smaller than expected when viewed with the affected eye, because the contracting membrane compresses the photoreceptors at the foveal center.
• Difficulty with reading and fine detail tasks: Near vision and reading speed are often disproportionately affected, even when distance vision appears relatively preserved on a standard eye chart.
• Aniseikonia: The image in the affected eye appears a different size than the image in the fellow eye, causing discomfort when both eyes are open together and sometimes leading to the brain suppressing the image from the worse eye.
• Monocular diplopia: In advanced membrane contraction, some patients see double with one eye alone.
• Loss of depth perception (stereopsis): When the images from the two eyes are significantly mismatched in clarity or size, depth perception is reduced.

Symptoms typically progress slowly over months to years, though the rate of progression varies. About 38% of cases worsen over time, about 31% remain stable, and about 31% partially regress or stabilize spontaneously over a 10-year observation period. Symptoms do not reliably predict which course a given membrane will follow.

A macular pucker is diagnosed by an ophthalmologist or a retinal specialist—a subspecialist in vitreoretinal diseases—through clinical examination combined with imaging, most importantly optical coherence tomography (OCT). The diagnosis is typically straightforward, but precise staging is important because it guides the timing of surgical intervention and sets realistic expectations for visual recovery.

• Visual acuity testing: Standard Snellen or Early Treatment Diabetic Retinopathy Study (ETDRS) chart measurement of best-corrected visual acuity in each eye. This establishes the functional baseline and is the primary metric used to decide when surgery is appropriate. The typical threshold for considering surgery is acuity of 20/50 or worse in the presence of significant symptoms.
• Dilated slit-lamp biomicroscopy: The doctor dilates the pupil and examines the macula through a specialized lens. The glistening cellophane-like reflection on the retinal surface, wrinkling of the retinal vessels, and visible membrane opacity are identified and graded using the Gass clinical system (grade 0, 1, or 2). This is the primary tool for initial detection.
• Spectral-domain optical coherence tomography (SD-OCT): the essential imaging test for macular pucker. OCT is a noninvasive scan that uses light waves to produce precise cross-sectional images of every retinal layer. It confirms the presence and nature of the membrane, measures the central retinal thickness (normally about 260 micrometers; in ERM typically 400 to 600 or more), assesses whether the foveal pit is intact or lost (stage 1 versus 2), identifies the ectopic inner foveal layer (EIFL) that marks stage 3 and 4 disease, and detects disruption of the ellipsoid zone—the photoreceptor layer—which predicts a worse surgical outcome. OCT also identifies any associated vitreomacular traction, lamellar macular hole, or macular pseudohole. It is the gold standard for staging, monitoring, surgical planning, and assessing postsurgical response.
• Amsler grid: a simple self-monitoring tool in which the patient looks at a 10 cm grid of straight lines at reading distance and reports any distortion, waviness, or blank areas. It is used both diagnostically and as a home monitoring tool for patients with known macular pucker to detect progression between visits.
• Fundus photography: Color photographs of the retina document the membrane’s appearance and the degree of retinal blood vessel distortion for the medical record and for comparison at follow-up visits.
• Fluorescein angiography or OCT-angiography: This is used selectively when a secondary cause, such as diabetic retinopathy or retinal vein occlusion, is suspected, or to differentiate a macular pseudohole (which has no leakage on angiography) from a true macular hole.
• Microperimetry: a specialized test that maps macular sensitivity point by point and quantifies metamorphopsia using M-charts. It provides functional information beyond what visual acuity alone captures, particularly useful when the patient’s symptom burden seems greater than the acuity measurement suggests.

A macular pucker is not treatable with eye drops or oral medications—there are no U.S. Food and Drug Administration (FDA)-approved pharmacological agents for epiretinal membrane. Ocriplasmin (Jetrea®), which is approved for a related condition called vitreomacular traction, is specifically not indicated for ERM and has been shown in clinical trials to be ineffective when an epiretinal membrane is present. Treatment choices, therefore, fall into two categories: watchful waiting for mild or asymptomatic disease, and surgery for symptomatic disease with meaningful visual impairment.

Observation is appropriate for patients whose macular pucker is at an early stage (Govetto stage 1), whose visual acuity is better than 20/40, and who do not have significant symptoms interfering with daily life. Many patients with early macular pucker can be followed with dilated examinations and OCT imaging every 6 to 12 months for years without requiring surgery. Patients should use the Amsler grid at home regularly to monitor for any increase in distortion between visits, and report promptly if they notice worsening. Corrective glasses optimized for the current prescription, and low-vision aids such as magnifiers or electronic reading devices, help maintain reading function during the observation period. For patients who are not surgical candidates for medical reasons, these nonsurgical measures remain the primary management strategy.

For patients with symptomatic macular pucker causing visual acuity of 20/50 or worse, progressive vision loss on serial examinations, or meaningful distortion affecting daily activities, the definitive treatment is pars plana vitrectomy (PPV) combined with surgical peeling of the epiretinal membrane. This outpatient procedure is the standard of care established since 1978 and performed with modern microincision vitreoretinal surgery (MIVS) systems using 23-gauge, 25-gauge, or 27-gauge instruments inserted through tiny self-sealing incisions in the white of the eye. Under a surgical microscope, the vitreoretinal surgeon first removes the vitreous gel, then uses vital stains—most commonly Brilliant Blue G dye—to improve visualization of the thin internal limiting membrane (ILM), the innermost structural layer of the retina. The epiretinal membrane is then carefully separated from the retinal surface using fine microforceps and gently peeled away. The ILM is also typically removed in the same procedure: this critical step releases any remaining traction on the fovea and removes the scaffold on which a new membrane could potentially regrow. Meta-analysis data support ILM peeling as the standard approach, showing better visual outcomes at 18 months and lower clinically significant recurrence rates (about 8%) compared to ERM peeling without ILM removal. Because vitrectomy surgery accelerates cataract formation in virtually all patients who still have their natural lens, most surgeons combine lens removal and intraocular lens implantation with the vitrectomy in the same surgical session, avoiding the need for a second operation. Visual improvement occurs in approximately 58–70% of patients. Eyes treated at earlier OCT stages achieve better final visual acuity—patients treated at stage 2 reach an average postoperative acuity of approximately 20/25, while stage 4 eyes typically reach approximately 20/44. All stages show statistically significant improvement. The main surgical risks include retinal detachment (approximately 5%), ERM recurrence (about 8% of significant recurrences at 29 months), and intraocular infection (rare, less than 0.05%). It is important to set realistic expectations: while visual acuity often improves meaningfully, metamorphopsia (distortion) may persist even after successful surgery, and full visual recovery can take up to three years as the retinal architecture gradually reorganizes after membrane removal.

For most people with a macular pucker, the condition follows a manageable course. The majority of early-stage cases are asymptomatic and may never require treatment. For those who develop symptoms, surgical treatment offers a high likelihood of meaningful visual improvement—and research consistently shows that quality of life improves substantially after surgery, driven primarily by reduction in distortion rather than solely by improved acuity on a standard eye chart. Near vision and reading ability—the functions most impaired by macular pucker—often improve more noticeably than distance acuity scores suggest. Visual improvement after surgery continues over time; most improvement occurs in the first six months, but gains can continue for up to three years as the retina reorganizes. Patients should be patient with the recovery process and attend all follow-up appointments. For the fellow (other) eye—which has a 35% chance of also having some degree of epiretinal membrane—regular dilated exams and home Amsler grid monitoring are important. Any new distortion in the better eye should prompt a call to the ophthalmologist rather than waiting for a scheduled visit.

To further your understanding of your diagnosis and to contribute to cutting-edge research, consider participating in a clinical trial so clinicians and scientists can learn more about causes, symptoms, treatment, and prevention of macular pucker and related disorders. Clinical research uses human volunteers to help researchers learn more about a disorder and perhaps find better ways to safely detect, treat, or prevent disease.

All types of volunteers are needed—those who are healthy or may have an illness or disease—of all different ages, sexes, races, and ethnicities to ensure that study results apply to as many people as possible, and that treatments will be safe and effective for everyone who will use them.